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Lung inflammation in cystic fibrosis (CF) is associated with 
an increased release from activated neutrophils of oxidants and 
proteinases. Free radical generation is not efficiently neutralized, 
and the major anti-proteinase, a,-proteinase inhibitor (a {-PI) is 
thought to be oxidatively inactivated. We hypothesized that 
enhanced antioxidant protection could represent an additional 
long-term strategy to attentuate the host inflammatory response. 
The effect on plasma neutrophil elastase/ar PI (NE/ar PI) com­
plex levels (as a marker of lung inflammation) and plasma 
malondialdehyde concentrations (as a marker of lipid peroxida-
»
tion) of additional oral /3-carotene supplementation was studied 
in 33 CF patients who had already received long-term vitamin E 
supplementation. In the presence of a more than 10-fold increase 
in plasma ß-carotene concentrations (mean ± SEM) (0.09 ± 
0.01 to 1,07 ± 0.19 }J,mol/L; p  <  0.0001), a small increase in 
plasma a-locopherol concentrations (23.8 ± 1.31 to 28.4 ±1.81 
¿¿mol/L; p — 0.02), and a more than 50% decrease in plasma
malondialdehyde concentrations (1.00 ± 0.07 to 0.46 ± 0.03 
/xmol/L; p <  0.0001), plasma NE/a,-PI complex levels de­
creased from 102.2 ± 16.0 to 83.0 ± 10.4 p,glL\ (p = 0.02), 
Plasma retinol concentrations increased (1.05 ± 0.06 to 1.23 ±
0,07 ju.mol/L; p  =  0.0001) due to conversion of ß-carotene to 
retinol, which could have contributed to the decrease in NE/ar PI 
complex levels. Based on these results, we speculate that efficient 
antioxidant supplementation could attenuate lung inflammation 
in CF. (Pediatr Res 40; 130-134, 1996)
Abbreviations
ttj-PI, a!-proteinase inhibitor 
CF, cystic fibrosis 
ELF, epithelial lining fluid 
MDA, malondialdehyde 
NE, neutrophil elastase 
TNF-a, tumor necrosis factor-a
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Lung disease in CF is characterized by chronic bacterial 
infection and a profound influx of neutrophils into the lower 
respiratory tract. Autoinjury from the host inflammatory re­
sponse is supposed to play an even more important role in 
disease progression than the total bacterial burden (1). Unin­
hibited elastase released from activated neutrophils is thought 
to significantly contribute to the destruction of lung connective 
tissue (2-4). However, NE exerts a number of additional 
actions (5-8), such as induction of IL-8 gene expression
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(which further augments neutrophil recruitment) and goblet 
cell hypeiplasia, enhancement of secretions by submucosal 
glands, and impairment of ciliary beating and complement- 
dependent phagocytosis of pathogens, all of which could con­
tribute to the severity of CF lung disease.
There is evidence of a proteinase-antiproteinase imbalance 
in favor of the former in CF airway secretions. Activated 
neutrophils release high amounts of NE and oxidants via 
NADPH or myeloperoxidase (9). Even though considerable 
quantities of the major antiproteinase a r PI are present in ELF 
and sputum of CF patients, only a small proportion is com- 
plexed to NE, and uninhibited NE activity is still detected 
(2-4), suggesting that a r PI is not fully functioning (3, 4, 10). 
Both proteolytic and oxidative inactivation of ar PI have been 
discussed as underlying mechanisms (3, 11-13). ar PI is easily 
oxidized at its methionyl residue, which reduces or completely 
abolishes its binding capacity (14, 15).
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NE/ar PI complex levels in peripheral blood are elevated in 
CF patients with pulmonary exacerbations and have been 
proposed as an early and sensitive marker of airway inflam­
mation in CF (16, 17). Large amounts of active NE are found 
in sputum and bronchoalveolar lavage fluid even after i.v. 
antibiotic treatment, and plasma levels of NE/ar PI complexes 
are not corrected to normal (4, 18) and increase rapidly after 
cessation of antibiotic therapy (4). Thus, additional strategies 
to depress pulmonary inflammation long-term may be of sig­
nificant importance.
Due to an increased release of oxidants from activated 
neutrophils on one hand and combined anti oxidant deficien­
cies, primarily due to not fully corrected fat malabsorption, on 
the other, CF patients exhibit an oxidant-antioxidant imbalance 
in favor of the former (19). As a result, excess lipid peroxida­
tion occurs (20, 21), as documented by increased plasma 
concentrations of MDA (21), an end product of oxidation of 
unsaturated fatty acids with three or more double bonds (22). 
Normalization of the impaired /3-carotene status of vitamin 
E-sufficient CF patients decreased lipid peroxidation to levels 
of healthy subjects (21).
We hypothesized that long-term supplementation with 
ß-carotene in vitamin E-sufficient CF patients will not only 
decrease lipid peroxidation, but also reduce the oxidant burden 
and protect a^ -PI against oxidative inactivation. In this obser­
vational study, we investigated the effect of 16 mo of ß-caro- 
tene supplementation on lipid peroxide and NE/a-, -PI complex 
levels in peripheral blood of vitamin E-sufficient CF patients,
METHODS
Subjects, Thirty-three patients (16 male, 17 female), ages 
2.3-30.5 y (median, 9.1 y), under long-term care at the CF 
outpatient clinic of the Department of Pediatrics, University of 
Zurich, with plasma ß-carotene concentrations below mean — 
2 SD of controls of the same age range and enrolled in a 16-mo 
oral ß-carotene supplementation study (23) were investigated. 
All but three patients had achieved plasma a-tocopherol con­
centrations >15.9 fimóUL (mean — 2 SD of Swiss population) 
(24) due to long-term oral a-tocopherol supplementation for at 
least 1 y before this study. Three patients received oral retinyl 
palmitate supplements (Arovit, Hoffmann La Roche Ltd.) and 
nine patients a multivitamin preparation (Pro to vit, Hoffmann 
La Roche Ltd.) on a long-term basis. These treatments were not 
changed during the study period. Thirteen patients were chron­
ically infected with Pseudomonas aeruginosa. Only one pa­
tient required i.v. antibiotic treatment at one of the two eval­
uations; it was started after blood was drawn for the study. 
Continuous antibiotic therapy by aerosol or orally in 10 pa­
tients was not changed during the study period, and six addi­
tional patients received antibiotics orally either at baseline or at
16 mo. Shwachman scores (25) were 88 ± 11 at study entry 
and 83 ± 11 at 16 mo, indicating a fairly stable disease status. 
Patients were in good nutritional status compared with Swiss 
reference values (26) (z scores; median; minimum, maximum) 
(weight, —0.43; —2.8,1.24; height, -0.28; —2.73, 1.86; upper 
arm circumference, —0.85; -2.31, 2.01).
Clinically healthy nonsmoking staff members (11 male, 23 
female), ages 19.9-42.8 y (median, 30.5 y), of the same 
hospital volunteered for this study, as it was ethically not 
acceptable to draw the necessary amounts of blood from 
healthy children.
During the study period, patients continued to take oral 
vitamin E supplements, either RRR-a-tocopherol (Multaben, 
Roche Pharma Schweiz Ltd., Reinach, Switzerland) or all-rac- 
a-tocopheryl acetate (Ephynal, Hoffmann La Roche Ltd., 
Basel, Switzerland) without changes in dose (330 ± 120 IU) 
and preparation. After the baseline evaluation, patients re­
ceived 0.5 mg/kg of body wt of ß-carotene orally in a single 
daily dose at breakfast (BellaCarotin, 3M Medica, Ltd., 
Borken, Germany), Details of dose and preparation have been 
described previously (21).
The study was approved by the Ethics Committee of the 
Department of Pediatrics, University of Zurich, and informed 
consent was obtained from the patients or their parents as well 
as from healthy controls.
Plasma antioxidants. After an overnight fast, blood was 
drawn in sterile plastic tubes containing 1.6 mg/mL K-EDTA 
(Sarstedt Monovette, Nümbrecht, Germany), protected from 
light by aluminum foil and centrifuged immediately at 2000 X 
g for 8 min. Plasma was stored at — 20°C for a maximum of 4 d 
before determination of plasma a-tocopherol, ß-carotene, and 
lycopene by HPLC (27). Plasma a-tocopherol to cholesterol 
ratios were calculated to correct for differences in cholesterol 
levels between patients and healthy controls.
Plasma lipid peroxides. Another aliquot of EDTA plasma 
was kept at — 70°C until determination of the MDA- 
thiobarbituric acid adduct by HPLC (28). Coefficients of vari­
ation of repeated MDA-thiobarbituric acid assays in our labo­
ratory were 4.4% (within run) and 6.9% (from run to run), 
respectively (21). For four patients blood was not available for 
MDA determination either at baseline or at 16 mo.
Plasma NE/ot^PI complexes. NE/ar PI complex levels 
were measured in plasma as described elsewhere (29), using an 
ELISA kit specific for these complexes (MERCK, Darmstadt, 
Germany, 2h version). Absorbance at 405 nm was recorded 
spectrophotometrically in an ELISA reader from Bio-Rad, 
Hercules, CA, and compared with values from known stan­
dards. The coefficient of variation of repeated measurements 
was 8.6%.
Plasma retinol concentrations were determined by HPLC 
(27). Indexes of inflammation (a,-acid glycoprotein, white 
blood cell count, bands) and nutritional status (albumin and 
cholesterol concentrations) were determined by routine meth­
ods. The pro inflammatory cytokine TNF-a levels were deter­
mined with a TNF-a-ELISA kit from Endogen, Boston, MA.
Statistical analysis. Due to nonconformity of the data with 
the normality assumption, Wilcoxon matched pairs signed 
ranks tests were used to compare study variables in patients at 
baseline and 16 mo, and Mann-Whitney U tests for compari­
sons between patients and controls. After log transformation, 
Pearson correlation was applied to study the relationship be­
tween different variables. Statgraphics Version 6 (STSC, Inc., 
Rockville, MD) was used for all statistical procedures. Differ-
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enees were considered significant at p <  0.05. All results are 
expressed as mean ± SD unless otherwise stated.
RESULTS
Plasma antioxidants. Baseline plasma ß-carotene concen­
trations were significantly lower in patients compared with 
healthy controls; they were frequently close to the detection 
limit. After 16 mo of ß-carotene supplementation they in­
creased significantly (p < 0.0001) and did no longer differ 
from controls (Table 1). Plasma ß-carotene concentrations did 
not increase in one patient due to liver involvement and in five 
additional patients due to poor compliance. Baseline plasma 
a-tocopherol concentrations and plasma a-tocopherol to cho­
lesterol ratios were well within the normal range due to long­
term oral vitamin E supplementation before study entry. Dur­
ing the observation period, a further increase in plasma 
a-tocopherol concentrations (p = 0.02) was observed (Table 
1), even though neither the preparation nor the dosage pre­
scribed for vitamin E supplementation had been changed. 
Possible explanations for this increase include improvement of 
compliance or a sparing effect of ß-carotene on a-tocopherol. 
Plasma a-tocopherol to cholesterol ratios increased accord­
ingly (7.27 ± 2.29 to 8.69 ± 2.17 mmol/mol; p = 0.009); at 16 
mo they were higher in patients than in controls (5.73 ± 0.63; 
p < 0.0001). Plasma lycopene concentrations were very low in 
patients (0.07 ± 0.07 ju,mol/L) throughout the study (controls, 
0.57 ± 0.19 jumol/L). Plasma albumin concentrations at study 
entry (38.7 ± 3.7 g/L) were well within the nomai range and 
did not change.
Lipid peroxides. Baseline plasma MDA concentrations were 
elevated in patients compared with controls (Table 1). They 
decreased significantly (p <  0.0001) and were lower in pa­
tients compared with controls at 16 mo (p = 0.004). Multiple 
regression analysis revealed that changes in MDA concentra­
tions (—0.57 ± 0.37 jLtmolTL) were related (R = 0.56) to 
changes in plasma a-tocopherol to cholesterol ratios (p —
0.003), but not to changes in plasma ß-carotene concentrations 
(p = 0.10).
NE/ar PI complexes. Baseline plasma NE/ar PI complex 
levels were more than twice as high compared with controls 
(p < 0.0001) (Table 1). At baseline, multiple regression
analysis showed a negative correlation (R = 0.42) between 
plasma NE/ar PI complex levels (log-transformed) and both 
plasma a-tocopherol (p = 0.05) and retinol concentrations 
(p = 0.03), but not with ß-carotene concentrations (log- 
transformed) (p = 0.06). There was a tendency of higher 
plasma NE/ar PI complex levels in patients with lower 
Shwachman scores, but the correlation did not reach statistical 
significance (r = —0.31, = 0.08). During ß-carotene sup­
plementation, plasma NE/ar PI complex levels decreased sig­
nificantly (p = 0.02), but values remained elevated compared 
with those of healthy controls (p = 0.0003) (Table 1). Multiple 
regression analysis did not show a correlation between the 
changes from baseline to 16 mo in NE/a^PI complex levels 
and the changes in plasma ß-carotene, a-tocopherol, and reti­
nol concentrations.
Additional investigations. Plasma a r PI concentrations 
(2,63 ± 0.60 g/L) were well within the normal range (2-4 
g/L). Plasma retinol concentrations increased (p = 0.0001) 
(Table 1), but remained lower than in controls (p < 0.0001). 
Commonly used indexes of inflammation (white blood cells, 
bands, a r acid glycoprotein) did not show any changes (Table 
1). TNF-a levels were below or close to the detection limit in
17 patients at baseline and 24 patients at 16 mo; they were 
>6.3 ng/L, the upper limit of normal, in 10 patients at baseline, 
decreased to normal in nine of these, and were elevated in four 
additional patients at 16 mo. These changes did not correlate 
with changes in NE/apPI complex levels. Patients were in a 
good nutritional status; they exhibited significant weight gain 
during the study period (p = 0.005) (Table 1).
DISCUSSION
Plasma NE/apPI complex levels have been proposed as an 
early and sensitive marker for monitoring pulmonary inflam­
mation in CF patients (16, 17). They correlate with bronchoal- 
veolar lavage fluid neutrophil counts (4) and, in infants and 
small children with CF, also with bronchoalveolar lavage 
NE/apPI complex levels (16). This study shows a decrease in 
elevated plasma NE/apPI complex levels during efficient oral 
ß-carotene supplementation in vitamin E-sufficient CF pa­
tients.
Table 1. Changes in NE/ar P I complexes, MDA and antioxidant concentrations, and weight gain during ß-carotene supplementation
Test
Patients (n = 33) Controls (n = 34)
Patients at 16 mo vs 
controlst P valueBaseline 16 months
B aseline vs 16 
mo* P value
NE/ar PI (jutg/L) 102.2 ± 16.0 83.0 ± 10.4 0.02 45.6 ± 3.2 0,0003
MDA (/¿mol/L) 1.01 ± 0.07 0,46 ± 0.03 <0.0001 0.61 ± 0,04 0.004
a-Tocopherol (ptmol/L) 23.8 ± 1.3 28.4 ± 1.8 0.02 28.7 ± 1.1 NS
ß-Carotene (¿imol/L) 0,09 ± 0.01 1.07 ±0.19 <0.0001 1.02 ±0.07 NS
Retinol (jumol/L) 1.05 ± 0.06 1.23 ± 0.07 0.0001 1.99 ± 0.09 <0.0001
Weight (z score) -0.55 ± 0.16 -0.39 ±0.17 0.005 n.d.
White blood cells (10*/L) 8.47 ± 0.52 8.52 ± 0.57 NS n.d.
Bands (%) 21.1 ± 1.9 22.1 ± 1.7 NS n.d.
a,-Acid glycoprotein (g/L) 1.06 ± 0.06 1.02 ± 0.06 NS n.d.
Values are mean ± SEM. NS = not significant; n.d. — not determined. 
* Wilcoxon matched pairs signed ranks tests, 
f Mann-Whitney U tests.
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Plasma ß-carotene concentrations reached values compara­
ble to those in healthy subjects, whereas a concomitant in­
crease in plasma a-tocopherol during the study period led to 
plasma a-tocopherol concentrations similar to, and plasma 
a-tocopherol to cholesterol ratios higher than, those of healthy 
controls. In addition, plasma retinol concentrations increased 
significantly, most likely due to ß-carotene conversion to 
retinol (30), but remained lower in patients compared with 
controls. This was accompanied by a more than 50% decrease 
in plasma MDA concentrations, resulting in values comparable 
to those in healthy subjects; this decrease correlated with the 
additional increase in plasma a-tocopherol to cholesterol ra­
tios, starting from values that were already normal, but not with 
the increase in plasma ß-carotene concentrations. Simulta­
neously, a statistically significant decrease in plasma NE/ar PI 
complex levels was observed. As a possible underlying mech­
anism we propose that ß-carotene and a-tocopherol were 
efficiently detoxifying oxidants released from activated neutro­
phils in airway secretions to less reactive forms (9, 31). In this 
context, we hypothesize that they interrupted the chain reaction 
of ongoing lipid peroxidation and provided enhanced protec­
tion of ar PI against oxidative inactivation. As a result, NE 
could have been more efficiently neutralized in ELF by forma­
tion of NE/ar PI complexes, and NE-mediated propagation of 
inflammation could have been attentuated. However, because 
this study focused on plasma only, the mechanisms leading to 
elevated plasma levels of NE/a^PI complexes and to the 
decrease during the study period remain speculative.
Baseline plasma NE/ar PI complex levels were related to 
plasma vitamin E and retinol concentrations, suggesting an 
impact on inflammation also of the vitamin A status in the 
study patients. Vitamin A has long been known to affect 
immune functions (32), and recent in vitro experiments (33) 
show that retinol exerts an inhibition of superoxide anion 
release from activated neutrophils. In our study, conversion of 
ß-carotene to retinol, not only in plasma but perhaps also in 
ELF, might have contributed to a decrease in the oxidant 
burden and, subsequently, to attenuation of lung inflammation.
The decrease in NE/ar PI complex levels occurred in the 
absence of a dos e-response relationship with the increase in 
plasma ß-carotene, a-tocopherol, and retinol concentrations. 
Data on antioxidant and retinol concentrations in ELF or on the 
cellular level were not obtained in this study. There is evidence 
that a-tocopherol levels in ELF can be augmented by oral 
vitamin E supplementation, and the oxidized metabolite, a-to­
copherol quinone, is present in ELF fluid (31, 34). So far, 
équivalant data on ß-carotene and retinol levels are not avail­
able. Besides between-subject differences in the amounts of 
antioxidants reaching the site of inflammation (compared with 
plasma concentrations), additional and more complex interac­
tions between different antioxidants, availability of lipids as the 
oxidizable substrate, and between-subject variability in lung 
inflammation itself may account for this lack of correlation.
During i.v. antibiotic treatment, plasma NE/a^PI complex 
levels in CF patients decrease by up to 50% (4, 17, 18), but 
remain higher than in healthy subjects (4, 17) and increase 
rapidly after cessation of antibiotic therapy in clinically stable 
patients (4). There is evidence of significant inflammation in
the airways of CF patients with clinically mild lung disease 
(35). Thus, long-term intervention to reduce inflammation 
might be beneficial even in patients without symptoms of acute 
exacerbations.
In this study, we investigated a relatively homogeneous 
patient population in stable clinical condition and with almost 
one third of patients on continuous oral antibiotic therapy. 
They were outpatients and, with few exceptions, free of acute 
pulmonary exacerbations. Patients were also efficiently supple­
mented with oral vitamin E before study entry, leading to 
plasma a-tocophei’ol concentrations similar to those in healthy 
subjects. The plasma NE/ar PI complex levels in our study 
population were considerably lower than in other studies of CF 
patients (4, 18, 36), but comparable to values for stable CF 
patients followed at yearly control visits (17). Conceivably, 
these relatively low values reflect the mild and stable pulmo­
nary disease status of these patients maintained on efficient 
antioxidant (oral vitamin E) and antibiotic therapy. Even in 
these patients with relatively mild disease, a significant reduc­
tion in NE/ar PI complex levels was achieved with additional 
ß-carotene supplementation.
Commonly used indexes of inflammation did not correlate 
with NE/ar PI complex levels, which is in line with other 
studies (16, 17), probably because NE/ar PI complex levels 
represent a more specific and sensitive marker of pulmonary 
inflammation. None of the standard indexes of inflammation 
changed during the study period. TNF-a levels were elevated 
only in a small proportion of patients, both at baseline and at 16 
mo. Perhaps due to normal values in most patients, we were 
unable to confirm the correlation between plasma NE/ar PI 
complex and TNF-a levels observed in another group of CF 
patients (36).
In conclusion, elevated NE/ar PI complex levels in plasma 
of clinically stable CF patients decreased during efficient anti­
oxidant supplementation, as did plasma lipid peroxide levels. 
Because this was an open, uncontrolled observational study 
that was limited to plasma levels, a controlled clinical trial, 
focusing on the effects of ß-carotene supplementation on free 
NE, NE/at-PI complexes, antioxidants, and lipid peroxides, 
both in plasma and bronchoalveolar lavage fluid, should now 
be conducted.
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